Free Trial
NASDAQ:BMEA

Biomea Fusion Q2 2025 Earnings Report

Biomea Fusion logo
$1.86 +0.03 (+1.64%)
Closing price 04:00 PM Eastern
Extended Trading
$1.86 +0.00 (+0.22%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.59
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Biomea Fusion Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biomea Fusion Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Biomea Fusion's Q3 2025 earnings is scheduled for Tuesday, November 4, 2025, with a conference call scheduled on Tuesday, October 28, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Biomea Fusion Earnings Headlines

Biomea Fusion (BMEA) Gets a Buy from Oppenheimer
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
Biomea Fusion (BMEA) Q2 Loss Drops 44%
See More Biomea Fusion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biomea Fusion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biomea Fusion and other key companies, straight to your email.

About Biomea Fusion

Biomea Fusion (NASDAQ:BMEA), a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

View Biomea Fusion Profile

More Earnings Resources from MarketBeat